Share

October 11, 2016; 87 (15) Editorial

Neurologists and the economics of MS treatment

Lighting candles, not cursing the darkness

Dennis Bourdette, Ruth Whitham
First published September 2, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003114
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
177

Share

Article Information

vol. 87 no. 15 1532-1533
DOI: 
https://doi.org/10.1212/WNL.0000000000003114
PubMed: 
27590289
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published September 2, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Dennis Bourdette, MD and
    2. Ruth Whitham, MD
  1. Dennis Bourdette, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) National Multiple Sclerosis Society, funding for travel (2) Consortium of MS Centers (3) Paralyzed Veterans of America

    Editorial Boards:

    1. (1) Current Neurology and Neuroscience Reports, Section Editor, 2008-present (I receive modest compensation for serving as Section Editor) (2) Neurology, Member Editorial Board, 2013-present

    Patents:

    1. (1) Use patent for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin (2) Patent pending for thyromimetic drugs for stimulating remyelination in multiple sclerosis.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) National MS Society, PI, April 2015- present (2) National MS Society, PI, April 2015-present

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) Use patent for the treatment of multiple sclerosis with cyclic peptide derivatives of cyclosporin, DebioPharma, 2014 and 2015

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ruth Whitham, MD
    3. Scientific Advisory Boards:

    1. I am a member of the data safety monitoring board for two clinical trials for treatment of neuromyelitis optica, sponsored by Chugai Pharmaceutical Co.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (D.B., R.W.), Oregon Health & Science University and MS Center of Excellence–West, VA Portland Health Care System (D.B.), Portland, OR.
  1. Correspondence to Dr. Bourdette: bourdett{at}ohsu.edu
View Full Text

Article usage

Article usage: September 2016 to December 2022

AbstractFullPdfSource
Sep 2016437028Highwire
Oct 20169293765Highwire
Nov 2016117621Highwire
Dec 201655310Highwire
Jan 20174823Highwire
Feb 201757107Highwire
Mar 20175853Highwire
Apr 201743133Highwire
May 20173751Highwire
Jun 20171222Highwire
Jul 20171701Highwire
Aug 20171535Highwire
Sep 2017901Highwire
Oct 20171440Highwire
Nov 2017500Highwire
Dec 20171210Highwire
Jan 20181011Highwire
Feb 2018710Highwire
Mar 20182131Highwire
Apr 20182811Highwire
May 20181043Highwire
Jun 20181800Highwire
Jul 2018700Highwire
Aug 20181800Highwire
Sep 20181432Highwire
Oct 20181200Highwire
Nov 2018911Highwire
Dec 2018901Highwire
Jan 20191300Highwire
Feb 2019400Highwire
Mar 2019600Highwire
Apr 20191410Highwire
May 2019600Highwire
Jun 2019410Highwire
Jul 2019410Highwire
Aug 2019620Highwire
Sep 2019200Highwire
Oct 2019720Highwire
Nov 20192400Highwire
Dec 2019300Highwire
Jan 20201305Highwire
Feb 20201141Highwire
Mar 2020500Highwire
Apr 2020711Highwire
May 2020200Highwire
Jun 2020601Highwire
Jul 2020400Highwire
Aug 2020200Highwire
Sep 2020300Highwire
Oct 2020400Highwire
Nov 20201210Highwire
Dec 2020700Highwire
Jan 2021721Highwire
Feb 20211800Highwire
Mar 20211100Highwire
Apr 20211221Highwire
May 20212513Highwire
Jun 2021300Highwire
Jul 2021911Highwire
Aug 2021400Highwire
Sep 2021600Highwire
Oct 20211700Highwire
Nov 2021410Highwire
Dec 2021700Highwire
Jan 2022400Highwire
Feb 20221300Highwire
Mar 20221300Highwire
Apr 20221400Highwire
May 2022800Highwire
Jun 2022802Highwire
Jul 2022301Highwire
Aug 2022500Highwire
Sep 20221100Highwire
Oct 2022110Highwire
Nov 2022900Highwire
Dec 2022800Highwire

Cited By...

Letters: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me